Fluoroquinolones: place in ocular therapy
- PMID: 11398907
- DOI: 10.2165/00003495-200161060-00004
Fluoroquinolones: place in ocular therapy
Abstract
The fluoroquinolones have become widely used antibacterial agents in the treatment of ocular infections, with topical, intravitreal and systemic routes of administration being used. In general, fluoroquinolones (such as ciprofloxacin, ofloxacin, lomefloxacin and norfloxacin) have good activity against gram-negative and gram-positive bacteria. Therapeutic concentrations are achieved in the cornea after topical administration so that the fluoroqinolones have largely replaced combination therapy for the treatment of bacterial keratitis. However, a second line agent is needed when resistance is likely, such as in disease caused by streptococcal species. Reversal of resistance to quinolones may not occur with withdrawal of the antibacterial. This stresses the importance of prudent prescribing to reduce the occurrence of resistance to quinolones. When used in therapeutic topical dosages, corneal toxicity does not occur. Similarly, retinal toxicity is not seen when fluoroquinolones are used at therapeutic dosages, systemically or topically. Corneal precipitation occurs, particularly with ciprofloxacin and to a lesser extent norfloxacin, but does not appear to interfere with healing. In the treatment of endophthalmitis there is reasonable penetration of systemic fluoroquinolones into the vitreous but sufficiently high concentrations to reach the minimum inhibitory concentration for 90% of isolates (MIC90) of all important micro-organisms may not be guaranteed. Systemic administration may be useful for prophylaxis after ocular trauma.
Similar articles
-
Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.Br J Ophthalmol. 1995 Jun;79(6):606-9. doi: 10.1136/bjo.79.6.606. Br J Ophthalmol. 1995. PMID: 7626579 Free PMC article.
-
Treatment of experimental bacterial keratitis with topical trovafloxacin.Arch Ophthalmol. 2004 Jan;122(1):65-9. doi: 10.1001/archopht.122.1.65. Arch Ophthalmol. 2004. PMID: 14718297
-
Lomefloxacin is an effective treatment of experimental bacterial keratitis.Cornea. 2001 Apr;20(3):306-8. doi: 10.1097/00003226-200104000-00013. Cornea. 2001. PMID: 11322421
-
Antibacterial agents in infections of the central nervous system and eye.Infect Dis Clin North Am. 1995 Sep;9(3):615-37. Infect Dis Clin North Am. 1995. PMID: 7490436 Review.
-
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Adv Ther. 2008. PMID: 18836691 Review.
Cited by
-
The Relationship between Ciprofloxacin Resistance and Genotypic Changes in S. aureus Ocular Isolates.Pathogens. 2022 Nov 15;11(11):1354. doi: 10.3390/pathogens11111354. Pathogens. 2022. PMID: 36422605 Free PMC article.
-
Fluorescence Quenching Studies on the Interactions between Chosen Fluoroquinolones and Selected Stable TEMPO and PROXYL Nitroxides.Int J Mol Sci. 2021 Jan 17;22(2):885. doi: 10.3390/ijms22020885. Int J Mol Sci. 2021. PMID: 33477329 Free PMC article.
-
Effects of fluoroquinolones and tetracyclines on mitochondria of human retinal MIO-M1 cells.Exp Eye Res. 2022 Jan;214:108857. doi: 10.1016/j.exer.2021.108857. Epub 2021 Nov 29. Exp Eye Res. 2022. PMID: 34856207 Free PMC article.
-
Flashes, floaters, and oral fluoroquinolones: is retinal detachment a worry?JAMA Ophthalmol. 2013 Jan;131(1):91-3. doi: 10.1001/jamaophthalmol.2013.559. JAMA Ophthalmol. 2013. PMID: 23307216 Free PMC article. No abstract available.
-
Ciprofloxacin-loaded bioadhesive hydrogels for ocular applications.Biomater Sci. 2020 Sep 15;8(18):5196-5209. doi: 10.1039/d0bm00935k. Biomater Sci. 2020. PMID: 32840522 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources